PR BHFT 0715 - Compounded mAbs - Cancer Therapies (replaces BHFT 0342)
Supply of Compounded Monoclonal Antibodies. Ranked framework split into 2 Lots as follows: Lot 1- High Volume Products - 5 molecules / all brands Pembrolizumab Rituximab Bevacizumab Daratumumab Nivolumab Lot 2 - Lower Volume Products - 14 molecules / all brands Pertuzumab/trastuzumab Brentuximab Cetuximab Atezolizumab Cemiplimab Avelumab Panitumumab Obinutuzumab Pertuzumab Trastuzumab Ipilimumab Isatuximab Polatuzumab
Buyer
Berkshire Healthcare NHS Foundation Trust
Value
Not provided
Published
11 May 2026
Closes
8 Jun 2026
Procurement details
Source
Atamis NHS Projects
Region
Berkshire
Procurement method
Not provided
Category
Not provided
Contract starts
Not provided
Contract ends
Not provided
CPV classifications
No CPV codes are available for this public record.
Lots
Lot default PR BHFT 0715 - Compounded mAbs - Cancer Therapies (replaces BHFT 0342)
Value not provided
PR BHFT 0715 - Compounded mAbs - Cancer Therapies (replaces BHFT 0342) from Berkshire Healthcare NHS Foundation Trust (unknown value) with deadline 08 Jun 2026.
Delivery: United Kingdom
Documents
Unlock document linkAtamis tender page
Not provided
Notice
Contains public sector information licensed under the Open Government Licence v3.0.